Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Recruiting

Phase 1

Phase 2

CD40L-augmented TILClinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Code:

NCT06961357

Conditions

Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cyclophosphamide

Fludarabine

Interleukin-2

TIL Product

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-11. This information was provided to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute on 2026-06-26.